Physician profile
Christopher P Fleming
NPI 1346246360
$811.00
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2021: $401 · 2022: $61.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $247.85 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $242.21 | 2019-2021 | |
| Ocular Therapeutix, INC. | $88.80 | 2019 | |
| Eyepoint US, INC. | $82.39 | 2021 | |
| Bausch & Lomb Americas INC. | $61.58 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.20 | 2019-2021 | |
| Allergan, INC. | $17.02 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.60 | 2021 | |
| Sun Pharmaceutical Industries INC. | $12.35 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.